Predictive Oncology Inc. (NASDAQ: POAI) has announced the pricing of two concurrent private placement transactions totaling approximately $344.4 million to support its new digital asset treasury strategy. The cancer-focused artificial intelligence company revealed that the strategy will center on ATH, the native token of the Aethir ecosystem, marking a significant departure from its traditional focus on drug discovery technologies.
The financing arrangement includes a $51.7 million cash private investment in public equity (PIPE) transaction alongside a $292.7 million crypto PIPE involving pre-funded warrants. According to the company announcement, proceeds from these transactions will be earmarked for ATH acquisition, working capital, and general corporate purposes. The substantial funding commitment underscores the company's strategic pivot toward digital asset treasury management while maintaining its core operations in cancer research.
Predictive Oncology has built its reputation on developing AI and machine learning technologies to expedite early drug discovery for cancer patients worldwide. The company's scientifically validated AI platform, PEDAL, can predict with 92% accuracy whether a tumor sample will respond to specific drug compounds. This capability allows for more informed selection of drug and tumor type combinations for subsequent laboratory testing. The company maintains one of the industry's largest biobanks with more than 150,000 assay-capable heterogenous human tumor samples, complemented by its wholly owned CLIA laboratory facility.
The digital asset treasury strategy represents a notable expansion beyond the company's traditional healthcare focus. By accumulating ATH tokens, Predictive Oncology is positioning itself within the growing cryptocurrency ecosystem while leveraging its financial resources to explore new investment avenues. The announcement was distributed through CryptoCurrencyWire, a specialized communications platform focusing on blockchain and cryptocurrency sectors that operates within the Dynamic Brand Portfolio at IBN. Additional information about the company is available at https://predictive-oncology.com/.
The substantial funding round comes at a time when traditional healthcare and technology companies are increasingly exploring digital asset strategies. Predictive Oncology's move signals growing institutional interest in cryptocurrency investments, particularly within companies that have established track records in specialized technological fields. The company's headquarters remain in Pittsburgh, Pennsylvania, where it continues to develop its AI-based drug discovery solutions for academic and industry partners.
